Recent Updates
Recently added Catalysts
AMRN Positive Sentiment Score: 70/100

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Key Takeaway: Amarin Corporation plc is set to participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024, where CEO Patrick Holt will engage in a fireside chat. This event will be webcasted live and also archived for later viewing. Amarin emphasizes its commitment to innovative cardiovascular disease management and scientific research. The company is actively expanding its commercial presence and communication with investors through various channels.

Market Sentiment Analysis

POSITIVE FACTORS

  • Amarin is participating in a prominent investor conference.
  • The company is showing active engagement with investors.
  • Amarin is evolving and expanding rapidly in cardiovascular management.

Full Press Release Details

DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference.
H.C. Wainwright 2nd Annual BioConnect Investor Conference (May 20 th , 2024; NYC)
Date/Time: May 20, 2024, 4:30 p.m. ET
Webcast: https://journey.ct.events/view/a719062a-400f-406f-82d4-2463ef546624
The session will be webcast live and archived on the Company’s website in the Investor Relations section under Events and Presentations at Events | Amarin Corporation plc.
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor & Media Inquiries:
Amarin Corporation plc

Frequently Asked Questions

When is Patrick Holt speaking at the conference?

Patrick Holt will speak on May 20, 2024, at 4:30 p.m. ET.

Where can I watch the Amarin conference session?

The session will be available via webcast at Amarin's website.

What is Amarin's focus in cardiovascular disease management?

Amarin focuses on advancing the treatment of cardiovascular risk beyond traditional methods.

How does Amarin communicate with investors?

Amarin uses its website and social media for investor communications and updates.

What is Amarin's email for investor inquiries?

You can contact Amarin at investor.relations@amarincorp.com.

Last updated: May 6, 2024